HRP20170851T1 - Postupak za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina - Google Patents
Postupak za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina Download PDFInfo
- Publication number
- HRP20170851T1 HRP20170851T1 HRP20170851TT HRP20170851T HRP20170851T1 HR P20170851 T1 HRP20170851 T1 HR P20170851T1 HR P20170851T T HRP20170851T T HR P20170851TT HR P20170851 T HRP20170851 T HR P20170851T HR P20170851 T1 HRP20170851 T1 HR P20170851T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- process according
- image
- organic solvent
- inclusive
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 26
- 235000010233 benzoic acid Nutrition 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000003960 organic solvent Substances 0.000 claims 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 6
- 238000006243 chemical reaction Methods 0.000 claims 6
- TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 150000004820 halides Chemical group 0.000 claims 5
- 230000002140 halogenating effect Effects 0.000 claims 5
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical group ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 4
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 claims 3
- MSSQOQPKGAMUSY-LEAFIULHSA-N 2-[1-[2-[(4r,6s)-8-chloro-6-(2,3-dimethoxyphenyl)-4,6-dihydropyrrolo[1,2-a][4,1]benzoxazepin-4-yl]acetyl]piperidin-4-yl]acetic acid Chemical compound COC1=CC=CC([C@@H]2C3=CC(Cl)=CC=C3N3C=CC=C3[C@@H](CC(=O)N3CCC(CC(O)=O)CC3)O2)=C1OC MSSQOQPKGAMUSY-LEAFIULHSA-N 0.000 claims 3
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 claims 3
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 claims 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 3
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 claims 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000003638 chemical reducing agent Substances 0.000 claims 3
- 229940125876 compound 15a Drugs 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 3
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 claims 2
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 claims 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000003586 protic polar solvent Substances 0.000 claims 2
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 claims 1
- TWYYFYNJOJGNFP-CUXYNZQBSA-N (2s,4r,5s,6s)-2-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-2-carbamoyl-4-[[(e,4s,6s)-4,6-dimethyloct-2-enoyl]oxymethyl]-5-hydroxy-1,3-dioxane-4,5,6-tricarboxylic acid Chemical compound O1[C@H](C(O)=O)[C@](C(O)=O)(O)[C@](COC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)(C(O)=O)O[C@]1(C(N)=O)CCC(=C)[C@@H](OC(C)=O)[C@H](C)CC1=CC=CC=C1 TWYYFYNJOJGNFP-CUXYNZQBSA-N 0.000 claims 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 claims 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical group [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 claims 1
- 238000005576 amination reaction Methods 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000000010 aprotic solvent Substances 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical group N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 claims 1
- 238000006880 cross-coupling reaction Methods 0.000 claims 1
- 238000005658 halogenation reaction Methods 0.000 claims 1
- 150000004678 hydrides Chemical group 0.000 claims 1
- 150000007529 inorganic bases Chemical class 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000006722 reduction reaction Methods 0.000 claims 1
- 239000011435 rock Substances 0.000 claims 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 claims 1
- -1 sulfonyl compound Chemical class 0.000 claims 1
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 150000003624 transition metals Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Claims (25)
1. Postupak za pripremu spoja formule 1:
[image]
obuhvaćajući korak:
ia) reagiranja spoja formule 6a:
[image]
pri čemu,
R je H, C1-6 alifatični, aril, aralkil, heteroaril, cikloalkil, ili heterocikloalkil;
R1 je nezavisno izabran od -RJ, -ORJ, -N(RJ)2, -NO2, halogena, -CN, -C1-4haloalkila, -C1-4haloalkoksi,
-C(O)N(RJ)2, -NRJC(O)RJ, -SORJ, -SO2RJ, -SO2N(RJ)2, -NRJSO2RJ, -CORJ, -CO2RJ, -NRJSO2N(RJ)2,-COCORJ;
RJ je vodik ili C1-6 alifatični;
O je cijeli broj od 0 do zaključno 3; i
p je cijeli broj od 0 do zaključno 5;
sa spojem formule 7a:
[image]
pri čemu,
A je fuzionirani heterocikloalkilni prsten;
R1 je nezavisno izabran od -RJ, -ORJ, -N(RJ)2, -NO2, halogena, -CN, -C1-4haloalkila, -C1-4 haloalkoksi,
-C(O)N(RJ)2, -NRJC(O)RJ, -SORJ, -SO2RJ, -SO2N(RJ)2,-NRJSO2RJ, -CORJ, -CO2RJ, -NRJSO2N(RJ)2, -COCORJ;
RJ je vodik ili C1-6 alifatični;
m je cijeli broj od 0 do zaključno 3;
n je cijeli broj od 1 do zaključno 4; i
X je halid ili OH;
u organskom otapalu u prisustvu baze;
pri čemu je spoj formule 6a pripremljen prema sljedećim koracima:
ib) osiguravanje spoja 2a i spoja 3a,
[image]
pri čemu,
R1 je nezavisno izabran od -RJ, -ORJ, -N(RJ)2, -NO2, halogena, -CN, -C1-4haloalkila, -C1-4haloalkoksi,
-C(O)N(RJ)2, -NRJC(O)RJ, -SORJ, -SO2RJ, -SO2N(RJ)2, -NRJSO2RJ, -CORJ, -CO2RJ, -NRJSO2N(RJ)2,
-COCORJ ;
RJ je vodik ili C1-6 alifatični;
o je cijeli broj od 0 do zaključno 4; i
p je cijeli broj od 0 do zaključno 5;
iib) unakrsno spajanje spoja 2a i spoja 3a u dvofaznoj smjesi sadržavajući vodu, organsko otapalo, bazu, i katalizator prijelaznog metala da se dobije spoje 4a,
[image]
pri čemu, R1, o, i p su kao što je definirano za spojeve 2a i 3a iznad;
iiib) oksidirajući spoj 4a da se dobije spoj 5a,
[image]
pri čemu, R1, o, i p su kao što je gore definirano za spoja 2a i 3a;
ivb) dodajući amino grupu na poziciju 6 piridil ostatka da se dobije spoj 6a,
[image]
pri čemu se reakcija aminacije izvodi u prisustvu sulfonil spoja, i pri čemu R je H, C1-6alifatični, aril, aralkil, heteroaril, cikloalkil, ili heterocikloalkil i R1, o, i p su kao što je gore definirano za spojeve 2a i 3a.
2. Postupak prema patentnom zahtjevu 1, pri čemu je spoj 7a pripremljen prema sljedećim koracima:
ic) reducirajući Spoj 10a u organskom otapalu:
[image]
pri čemu,
A je fuzionirani heterocikloalkil;
R1 je nezavisno izabran od -RJ, -ORJ, -N(RJ)2, -NO2, halogena, -CN, -C1-4haloalkila, -C1-4haloalkoksi,
-C(O)N(RJ)2, -NRJC(O)RJ, -SORJ, -SO2RJ, -SO2N(RJ)2,-NRJSO2RJ, -CORJ, -CO2RJ, -NRJSO2N(RJ)2, -COCORJ;
RJ je vodik ili C1-6 alifatični; i
m je cijeli broj od 0 do zaključno 3,
sa reducirajućim agensom da se dobije Spoj 11a:
[image]
pri čemu, prsten A, R1, i m su kao što je definirano u Spoju 10a iznad;
iic) reagiranjem Spoja 11a sa prvim halogenirajućim agensom u organskom rastvaraču da se dobije Spoj 12a:
[image]
pri čemu, prsten A, R1, i m su kao što je definirano u Spoju 10a iznad, i Hal je halid;
iiic) reagiranjem Spoja 12a sa cijanidom da se dobije Spoj 13a:
[image]
pri čemu, prsten A, R1, i m su kao što je definirano u Spoju 10a iznad;
ivc) reagiranjem Spoja 13a sa spojem formule 13aa u prisustvu baze:
[image]
pri čemu,
Hal je halid; i
q je cijeli broj od 0 do zaključno 3; da se dobije spoje formule 14a:
[image]
pri čemu,
r je cijeli broj od 1 do zaključno 4; i
prsten A, R1, i m su kao što je definirano u Spoju 10a iznad;
vc) sekvencijalnim reagiranjem Spoja 14a sa hidroksidnom bazom i kiselinom da se formira Spoj 15a, koji je spoj 7a, kada je X = OH:
[image]
pri čemu, r, prsten A, R1, i m su kao što je definirano u Spoju 14a iznad; i
vic) reagiranjem Spoja 15a sa drugim agensom za halogeniranje u organskom otapalu da se formira Spoj 16a, koji je spoj 7a kada je X = halid:
[image]
pri čemu,
Hal je halid; i
r, prsten A, R1, i m su kao što je definirano u Spoju 14a iznad.
3. Postupak prema patentnom zahtjevu 2, pri čemu je organsko otapalo korišteno u koraku ic, neprotonsko otapalo.
4. Postupak prema patentnom zahtjevu 2, pri čemu je organsko otapalo korišteno u koraku ic, toluen.
5. Postupak prema patentnom zahtjevu 2, pri čemu je reducirajući agens hidrid.
6. Postupak prema patentnom zahtjevu 2, pri čemu je reducirajući agens natrij bis(2-metoksietoksi)aluminij hidrid.
7. Postupak prema patentnom zahtjevu 2, pri čemu se reakcija redukcije odvija između 15°C i 40°C.
8. Postupak prema patentnom zahtjevu 2, pri čemu je organsko otapalo korišteno u koraku iic, neprotonsko otapalo.
9. Postupak prema patentnom zahtjevu 2, pri čemu je organsko otapalo korišteno u koraku iic, metil t-butil eter.
10. Postupak prema patentnom zahtjevu 2, pri čemu je prvi halogenirajući agens tionil klorid.
11. Postupak prema patentnom zahtjevu 2, pri čemu se reakcija Spoja 11a sa prvom reakcijom halogeniziranja odvija između 15°C i 30°C.
12. Postupak prema patentnom zahtjevu 2, pri čemu je cijanid, natrij cijanid.
13. Postupak prema patentnom zahtjevu 2, pri čemu se reakcija Spoja 12a sa cijanidom odvija između 30°C i 40°C.
14. Postupak prema patentnom zahtjevu 2, pri čemu je baza u koraku ivc, neorganska baza.
15. Postupak prema patentnom zahtjevu 2, pri čemu je baza u koraku ivc, kalij hidroksid.
16. Postupak prema patentnom zahtjevu 2, pri čemu je Spoj 13aa, 1-bromo-2-kloroetan.
17. Postupak prema patentnom zahtjevu 2, pri čemu se reakcija Spoja 13a sa spojem formule 13aa odvija između 50°C i 90°C.
18. Postupak prema patentnom zahtjevu 2, pri čemu je hidroksidna baza natrij hidroksid.
19. Postupak prema patentnom zahtjevu 2, pri čemu je kiselina u koraku vc, neorganska kiselina.
20. Postupak prema patentnom zahtjevu 2, pri čemu je kiselina u koraku vc, klorovodična kiselina.
21. Postupak prema patentnom zahtjevu 2, pri čemu se sekvencijalna reakcija Spoja 14a sa hidroksidnom bazom i kiselinom odvija između 70°C i 90°C.
22. Postupak prema patentnom zahtjevu 2, pri čemu je organsko otapalo u koraku vic, neprotonsko otapalo.
23. Postupak prema patentnom zahtjevu 2, pri čemu je organski rastvarač u koraku vic, toluen.
24. Postupak prema patentnom zahtjevu 2, pri čemu je drugi halogenirajući agens tionil klorid.
25. Postupak prema patentnom zahtjevu 2, pri čemu se reakcija Spoja 15a sa drugim halogenirajućim agensom odvija između 40°C i 80°C.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1218107P | 2007-12-07 | 2007-12-07 | |
US10957308P | 2008-10-30 | 2008-10-30 | |
EP12196511.5A EP2639223B1 (en) | 2007-12-07 | 2008-12-04 | Process for producing cycloalkylcarboxiamido-pyridine benzoic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170851T1 true HRP20170851T1 (hr) | 2017-08-25 |
Family
ID=40329178
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130418AT HRP20130418T1 (en) | 2007-12-07 | 2013-05-10 | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
HRP20161543TT HRP20161543T1 (hr) | 2007-12-07 | 2016-11-21 | Proces za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina |
HRP20161572TT HRP20161572T1 (hr) | 2007-12-07 | 2016-11-24 | Postupak za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina |
HRP20170851TT HRP20170851T1 (hr) | 2007-12-07 | 2017-06-05 | Postupak za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130418AT HRP20130418T1 (en) | 2007-12-07 | 2013-05-10 | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
HRP20161543TT HRP20161543T1 (hr) | 2007-12-07 | 2016-11-21 | Proces za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina |
HRP20161572TT HRP20161572T1 (hr) | 2007-12-07 | 2016-11-24 | Postupak za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina |
Country Status (26)
Country | Link |
---|---|
US (4) | US8124781B2 (hr) |
EP (4) | EP2639222B1 (hr) |
JP (4) | JP5702149B2 (hr) |
KR (3) | KR20150066608A (hr) |
CN (2) | CN101910134B (hr) |
AU (1) | AU2008335440B2 (hr) |
BR (1) | BRPI0820902A2 (hr) |
CA (3) | CA2989620C (hr) |
CL (1) | CL2010000631A1 (hr) |
CY (4) | CY1113985T1 (hr) |
DK (4) | DK2639223T3 (hr) |
EA (1) | EA201070700A1 (hr) |
ES (4) | ES2604555T3 (hr) |
HK (2) | HK1146820A1 (hr) |
HR (4) | HRP20130418T1 (hr) |
HU (3) | HUE032268T2 (hr) |
IL (4) | IL206205A (hr) |
LT (3) | LT2639223T (hr) |
MX (4) | MX365732B (hr) |
NZ (3) | NZ599684A (hr) |
PL (4) | PL2639224T3 (hr) |
PT (4) | PT2639224T (hr) |
RS (4) | RS56083B1 (hr) |
SI (4) | SI2639223T1 (hr) |
WO (1) | WO2009076142A2 (hr) |
ZA (1) | ZA201003624B (hr) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
RU2006111093A (ru) | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
ZA200604578B (en) * | 2003-11-14 | 2008-05-28 | Vertex Pharma | Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
ME02156B (me) | 2004-06-24 | 2015-10-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
CA2618057A1 (en) * | 2005-08-11 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
ES2431388T3 (es) | 2005-11-08 | 2013-11-26 | Vertex Pharmaceuticals Incorporated | Compuesto heterocíclico útil como un modulador de transportadores de casete de unión a ATP |
NZ569327A (en) | 2005-12-28 | 2011-09-30 | Vertex Pharma | 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis |
US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
PT1993360T (pt) | 2005-12-28 | 2017-05-25 | Vertex Pharma | Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
CN101460489A (zh) | 2006-04-07 | 2009-06-17 | 弗特克斯药品有限公司 | Atp-结合盒转运蛋白调节剂 |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
NZ581309A (en) * | 2007-05-25 | 2012-02-24 | Vertex Pharma | Ion channel modulators and methods of use |
NZ583420A (en) | 2007-08-24 | 2012-06-29 | Vertex Pharma | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis |
NZ585980A (en) | 2007-11-16 | 2012-04-27 | Vertex Pharma | Isoquinoline modulators of atp-binding cassette transporters |
JP2011506331A (ja) * | 2007-12-07 | 2011-03-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の処方物 |
RS56083B1 (sr) | 2007-12-07 | 2017-10-31 | Vertex Pharma | Proces za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
SG186638A1 (en) * | 2007-12-07 | 2013-01-30 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
WO2009108657A2 (en) | 2008-02-28 | 2009-09-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
PT2615085E (pt) | 2008-03-31 | 2015-10-09 | Vertex Pharma | Derivados piridilo como moduladores cftr |
AR073709A1 (es) | 2008-09-29 | 2010-11-24 | Vertex Pharma | Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico |
KR20110074917A (ko) | 2008-10-23 | 2011-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도도 조정자의 조절인자 |
CA3071058C (en) | 2009-03-20 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
NZ602838A (en) | 2010-04-07 | 2015-06-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
PL2555754T3 (pl) | 2010-04-07 | 2016-09-30 | Formy stałe kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego | |
JP2013525371A (ja) | 2010-04-22 | 2013-06-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | シクロアルキルカルボキサミド−インドール化合物の製造方法 |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
US9254291B2 (en) | 2011-11-08 | 2016-02-09 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
AU2013226076B2 (en) | 2012-02-27 | 2017-11-16 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
US9783529B2 (en) | 2013-03-13 | 2017-10-10 | Flatley Discovery Lab, Llc | Pyridazinone compounds and methods for the treatment of cystic fibrosis |
KR102280372B1 (ko) | 2013-11-12 | 2021-07-22 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법 |
EP4223294A1 (en) | 2014-04-15 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
LT3203840T (lt) | 2014-10-06 | 2020-10-26 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai |
EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
AU2015350049B2 (en) | 2014-11-18 | 2021-08-19 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
EP4272820A3 (en) * | 2015-05-29 | 2024-01-03 | Emory University | 2-amino-n'-benzylideneacetohydrazides and derivatives for the management of cftr protein mediated diseases |
EP3302466A4 (en) | 2015-05-29 | 2018-12-26 | Emory University | 3-(phenyl)-n-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of cftr protein mediated diseases |
WO2017017696A1 (en) * | 2015-07-27 | 2017-02-02 | Mylan Laboratories Limited | Process for the preparation of lumacaftor |
CN105130949B (zh) * | 2015-09-02 | 2019-01-29 | 阜新奥瑞凯新材料有限公司 | 1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙基腈的制备方法 |
WO2017056109A2 (en) | 2015-09-29 | 2017-04-06 | Mylan Laboratories Limited | Novel forms of lumacaftor and processes for the preparation thereof |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
CN107033120B (zh) * | 2016-02-03 | 2020-03-17 | 苏州旺山旺水生物医药有限公司 | 2-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)乙氰的制备方法 |
WO2017137900A1 (en) | 2016-02-10 | 2017-08-17 | Lupin Limited | Amorphous lumacaftor and its solid dispersion |
GEP20217329B (en) | 2016-09-30 | 2021-12-10 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
WO2018107040A1 (en) * | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | 1-(2-fluorophenyl)-n-[1-(2-fluoro-4-pyridyl)pyrazol-3-yl]cyclopropanecarboxamide, its solid forms and pharmaceutical uses thereof |
EP3812379A1 (en) | 2016-12-09 | 2021-04-28 | Vertex Pharmaceuticals Incorporated | Crystalline form of a n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide for treating cystic fibrosis |
TW201833087A (zh) * | 2016-12-09 | 2018-09-16 | 美商維泰克斯製藥公司 | 用於減少非常長鏈脂肪酸含量之1,3-取代吡唑化合物 |
US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
AU2018380426B2 (en) | 2017-12-08 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
US11066417B2 (en) | 2018-02-15 | 2021-07-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
WO2019200246A1 (en) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
KR20220067551A (ko) | 2019-08-14 | 2022-05-24 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막관통 전도도 조절자의 조절제 |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
US20230373974A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20230382924A1 (en) | 2020-10-07 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CA3197857A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076618A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076625A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20230373935A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076622A2 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225761A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20230416275A1 (en) | 2020-10-07 | 2023-12-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20230373939A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
WO2023150237A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023196429A1 (en) | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
Family Cites Families (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3758475A (en) * | 1971-07-20 | 1973-09-11 | Sandoz Ag | Pyrido(2,3-d)pyrimidin 2 ones |
IT1226048B (it) | 1981-12-14 | 1990-12-10 | Medea Res Srl | Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative |
EP0081756B1 (en) | 1981-12-14 | 1985-05-15 | MEDEA RESEARCH S.r.l. | New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions |
US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
US5981714A (en) | 1990-03-05 | 1999-11-09 | Genzyme Corporation | Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor |
JP3167762B2 (ja) * | 1990-11-27 | 2001-05-21 | 武田薬品工業株式会社 | ピリドピリダジン誘導体およびその用途 |
US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
CA2107196A1 (en) | 1992-09-29 | 1994-03-30 | Mitsubishi Chemical Corporation | Carboxamide derivatives |
GB9317764D0 (en) | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
ES2129679T3 (es) * | 1993-10-21 | 1999-06-16 | Searle & Co | Derivados que contienen el grupo amidino, utiles como inhibidores de la sintasa de oxido nitrico. |
DE4405712A1 (de) * | 1994-02-23 | 1995-08-24 | Basf Ag | Substituierte Naphthyridine und deren Verwendung |
IL113313A (en) * | 1994-04-11 | 1999-09-22 | Sankyo Co | Heterocyclic compounds and pharmaceutical compositions containing the same |
CZ289031B6 (cs) | 1994-09-27 | 2001-10-17 | Janssen Pharmaceutica N. V. | Deriváty N-substituovaných piperidinylových bicyklických benzoátů |
US5656256A (en) | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
US5510379A (en) | 1994-12-19 | 1996-04-23 | Warner-Lambert Company | Sulfonate ACAT inhibitors |
EA002270B1 (ru) * | 1996-03-29 | 2002-02-28 | Пфайзер Инк. | Производные 6-фенилпиридил-2-амина |
WO1997036876A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6849733B1 (en) | 1996-08-23 | 2005-02-01 | Agouron Pharmaceuticals, Inc. | Neuropeptide-Y ligands |
JP2002511054A (ja) | 1996-12-30 | 2002-04-09 | メルク エンド カンパニー インコーポレーテッド | ファルネシル蛋白トランスフェラーゼ阻害薬 |
US5948814A (en) | 1997-02-20 | 1999-09-07 | The Curators Of The University Of Missouri | Genistein for the treatment of cystic fibrosis |
WO1998047868A1 (en) | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists |
TR200000896T2 (tr) * | 1997-10-02 | 2000-09-21 | Sankyo Company Limited | Amidokarboksilik asit türevleri. |
EP1054996B1 (en) | 1998-02-17 | 2004-01-28 | G.D. SEARLE & CO. | Process for the enzymatic resolution of lactams |
ES2188264T3 (es) | 1998-06-08 | 2003-06-16 | Schering Corp | Antagonistas del receptor del neuropeptido y5. |
US6426331B1 (en) * | 1998-07-08 | 2002-07-30 | Tularik Inc. | Inhibitors of STAT function |
AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
CA2347770A1 (en) | 1998-12-18 | 2000-06-22 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
KR100437587B1 (ko) | 1999-02-24 | 2004-06-30 | 에프. 호프만-라 로슈 아게 | 3-페닐피리딘 유도체 및 그의 뉴로키닌-1 수용체길항제로서의 용도 |
RU2238264C2 (ru) | 1999-02-24 | 2004-10-20 | Ф.Хоффманн-Ля Рош Аг | Производные бензола или пиридина и фармацевтическая композиция на их основе |
DK1035115T3 (da) * | 1999-02-24 | 2005-01-24 | Hoffmann La Roche | 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
WO2000078733A1 (de) | 1999-06-18 | 2000-12-28 | Bayer Aktiengesellschaft | Phenoxyfluorpyrimidine |
UA74539C2 (en) | 1999-12-08 | 2006-01-16 | Pharmacia Corp | Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants) |
WO2001046165A2 (en) | 1999-12-16 | 2001-06-28 | Novartis Ag | N-heteroaryl-amides and their use as parasiticides |
WO2001051919A2 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
WO2001054690A1 (en) | 2000-01-28 | 2001-08-02 | Biogen, Inc. | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses |
AU2001234689A1 (en) | 2000-02-01 | 2001-08-14 | Cor Therapeutics, Inc. | Bivalent phenylene inhibitors of factor xa |
US20010047100A1 (en) | 2000-04-26 | 2001-11-29 | Kjaersgaard Hans Joergen | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
WO2001083517A1 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Stat4 and stat6 binding dipeptide derivatives |
WO2001092235A1 (en) | 2000-06-01 | 2001-12-06 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
EP1317452B1 (en) * | 2000-09-15 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
JP4272338B2 (ja) * | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
WO2002028348A2 (en) | 2000-10-04 | 2002-04-11 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of cystic fibrosis |
GB2367816A (en) | 2000-10-09 | 2002-04-17 | Bayer Ag | Urea- and thiourea-containing derivatives of beta-amino acids |
DE60104014T2 (de) | 2000-10-20 | 2005-08-11 | Merck Patent Gmbh | Chirale binaphtol-verbindungen |
US6884782B2 (en) | 2000-11-08 | 2005-04-26 | Amgen Inc. | STAT modulators |
JP4323802B2 (ja) * | 2000-12-01 | 2009-09-02 | エムジーアイ・ジーピー・インコーポレーテッド | 化合物およびその使用 |
JP2002197001A (ja) | 2000-12-27 | 2002-07-12 | Fujitsu Ltd | クライアント・サーバ型のシステムにおける情報の通信方法 |
GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US6531597B2 (en) | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
WO2003084997A1 (en) * | 2001-04-10 | 2003-10-16 | Transtech Pharma, Inc. | Probes, systems and methods for drug discovery |
BR0209151A (pt) | 2001-04-23 | 2004-07-13 | Hoffmann La Roche | Uso de antagonistas de receptor nk-1 contra hiperplasia prostática benigna |
SK15432003A3 (sk) * | 2001-05-22 | 2004-05-04 | Neurogen Corporation | 5-Substituované 2-arylpyridíny |
JP2003015528A (ja) | 2001-06-28 | 2003-01-17 | Mint Bureau Ministry Of Finance | 画像表示構造 |
US20030083345A1 (en) | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
US20030144350A1 (en) | 2001-07-20 | 2003-07-31 | Adipogenix, Inc. | Fat accumulation-modulation compounds |
US7427623B2 (en) | 2001-09-11 | 2008-09-23 | Smithkline Beecham Corporation | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof |
PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
JP2003221386A (ja) * | 2001-11-26 | 2003-08-05 | Takeda Chem Ind Ltd | 二環性誘導体、その製造法およびその用途 |
CZ2004747A3 (cs) | 2001-12-21 | 2004-11-10 | Novo Nordisk A/S | Deriváty amidů jako GK aktivátory |
TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
GB0221443D0 (en) * | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
EP1554271A1 (en) | 2002-10-15 | 2005-07-20 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
US7514431B2 (en) | 2002-10-30 | 2009-04-07 | Merck & Co., Inc. | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity |
JP2006512338A (ja) * | 2002-12-12 | 2006-04-13 | ファルマシア・コーポレーション | マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−2阻害剤としてのアミノシアノピリジンの使用法 |
DK1585739T3 (da) | 2003-01-06 | 2011-06-20 | Lilly Co Eli | Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer |
CA2755297A1 (en) * | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
WO2004080972A1 (en) * | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
CN1812977A (zh) | 2003-04-30 | 2006-08-02 | 药物研发有限责任公司 | 取代羧酸 |
DE602004022819D1 (de) * | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
AU2004253541B2 (en) | 2003-06-27 | 2010-10-28 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Amphiphilic pyridinium compounds, method of making and use thereof |
JP2005053902A (ja) * | 2003-07-18 | 2005-03-03 | Nippon Nohyaku Co Ltd | フェニルピリジン類、その中間体及びこれを有効成分とする除草剤 |
CA2537829A1 (en) * | 2003-09-05 | 2005-03-17 | Neurogen Corporation | Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands |
RU2006111093A (ru) | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
US20050070718A1 (en) * | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
AU2004279855A1 (en) * | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups |
FR2861304B1 (fr) * | 2003-10-23 | 2008-07-18 | Univ Grenoble 1 | Modulateurs des canaux cftr |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
ZA200604578B (en) * | 2003-11-14 | 2008-05-28 | Vertex Pharma | Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters |
EP1687001A2 (en) | 2003-11-19 | 2006-08-09 | Glaxo Group Limited | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
EP3219709B1 (en) | 2004-01-30 | 2020-03-18 | Vertex Pharmaceuticals Incorporated | Intermediate compound of modulators of atp-binding cassette transporters |
CN100567270C (zh) * | 2004-02-19 | 2009-12-09 | 万有制药株式会社 | 磺酰胺衍生物 |
ES2241496B1 (es) * | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
WO2005115399A2 (en) * | 2004-04-16 | 2005-12-08 | Neurogen Corporation | Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands |
US7585885B2 (en) * | 2004-04-22 | 2009-09-08 | Eli Lilly And Company | Pyrrolidine derivatives useful as BACE inhibitors |
JP2007533740A (ja) * | 2004-04-22 | 2007-11-22 | イーライ リリー アンド カンパニー | Bace阻害剤としてのアミド |
EP1766062A4 (en) | 2004-06-01 | 2008-07-09 | Tm Bioscience Corp | METHOD FOR DETECTING MUTATIONS ASSOCIATED WITH CYSTIC FIBROSIS |
US20140343098A1 (en) | 2004-06-24 | 2014-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
ME02156B (me) * | 2004-06-24 | 2015-10-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
MX2007000308A (es) | 2004-07-01 | 2007-04-10 | Warner Lambert Co | Preparacion de composiciones farmaceuticas que contienen nanoparticulas. |
US8715727B2 (en) | 2004-07-02 | 2014-05-06 | Shionogi Inc. | Tablet for pulsed delivery |
CN1993339B (zh) | 2004-08-06 | 2013-05-22 | 大塚制药株式会社 | 芳香化合物 |
US20060069110A1 (en) * | 2004-09-27 | 2006-03-30 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
WO2006040520A1 (en) | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinazoline derivatives |
CA2587461A1 (en) * | 2004-11-15 | 2006-05-18 | Pfizer Products Inc. | Azabenzoxazoles for the treatment of cns disorders |
ME01868B (me) | 2004-12-15 | 2010-10-31 | Dompe Pha R Ma Spa Res & Mfg | Derivati 2-arilpropionske kiseline i farmaceutske smeše, koje ih sadrže |
JP4790260B2 (ja) * | 2004-12-22 | 2011-10-12 | 出光興産株式会社 | アントラセン誘導体を用いた有機エレクトロルミネッセンス素子 |
US20080146612A1 (en) | 2005-01-27 | 2008-06-19 | Astrazeneca Ab | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor |
US7888374B2 (en) * | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
US20090048258A1 (en) * | 2005-02-01 | 2009-02-19 | Masaki Ogino | Amide Compound |
US8242149B2 (en) | 2005-03-11 | 2012-08-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
TW200716594A (en) * | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
BRPI0610850A2 (pt) | 2005-04-19 | 2008-12-02 | Bayer Pharmaceuticals Corp | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
CN101223146A (zh) * | 2005-05-24 | 2008-07-16 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
JP2008545744A (ja) | 2005-06-02 | 2008-12-18 | バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト | フェニルアルキル置換ヘテロアリール誘導体 |
EP1919875A2 (en) | 2005-06-21 | 2008-05-14 | Astex Therapeutics Limited | Pyrazole derivatives and their use as pka and pkb modulators |
ES2367844T3 (es) | 2005-08-11 | 2011-11-10 | Vertex Pharmaceuticals, Inc. | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística. |
CA2618057A1 (en) * | 2005-08-11 | 2007-02-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
MY145713A (en) | 2005-09-09 | 2012-03-30 | Smithkline Beecham Corp | Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders |
MY143784A (en) | 2005-09-23 | 2011-07-15 | Hoffmann La Roche | Novel dosage formulation |
CA2624683A1 (en) * | 2005-10-06 | 2007-04-19 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
BRPI0618417A2 (pt) | 2005-10-19 | 2012-07-31 | Gruenenthal Chemie | novos ligandos de receptores de vanilàide e seu uso para produzir medicamentos |
ES2431388T3 (es) | 2005-11-08 | 2013-11-26 | Vertex Pharmaceuticals Incorporated | Compuesto heterocíclico útil como un modulador de transportadores de casete de unión a ATP |
US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
WO2007054480A1 (en) * | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
CN101326182B (zh) | 2005-12-05 | 2011-09-28 | 史密丝克莱恩比彻姆公司 | 2-嘧啶基吡唑并吡啶ErbB激酶抑制剂 |
EP1968568A4 (en) * | 2005-12-22 | 2011-04-13 | Glaxosmithkline Llc | HEMMER OF NUTS ACTIVITY |
CA2634113A1 (en) | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of abc transporters |
CA2635214A1 (en) | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
NZ569327A (en) | 2005-12-28 | 2011-09-30 | Vertex Pharma | 1-(benzo [d] [1,3] dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-binding cassette transporters for the treatment of cystic fibrosis |
PT1993360T (pt) | 2005-12-28 | 2017-05-25 | Vertex Pharma | Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
CN101460489A (zh) | 2006-04-07 | 2009-06-17 | 弗特克斯药品有限公司 | Atp-结合盒转运蛋白调节剂 |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
AU2007249269A1 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
AU2007351454B2 (en) | 2006-11-03 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
KR20090083408A (ko) | 2006-11-27 | 2009-08-03 | 노파르티스 아게 | 치환된 디히드로이미다졸 및 종양 치료에서의 그의 용도 |
US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
HUE025553T2 (en) | 2007-05-25 | 2016-02-29 | Vertex Pharma | CFTR modulators |
US20110177999A1 (en) * | 2007-08-09 | 2011-07-21 | Vertex Pharmaceuticals Incorporated | Therapeutic Combinations Useful in Treating CFTR Related Diseases |
NZ583420A (en) | 2007-08-24 | 2012-06-29 | Vertex Pharma | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis |
DE102007042754A1 (de) | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
CN101821266B (zh) | 2007-09-14 | 2014-03-12 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
AU2008301907B2 (en) | 2007-09-14 | 2014-02-20 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
FR2921657A1 (fr) * | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
NZ585980A (en) | 2007-11-16 | 2012-04-27 | Vertex Pharma | Isoquinoline modulators of atp-binding cassette transporters |
SG186638A1 (en) | 2007-12-07 | 2013-01-30 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
JP2011506331A (ja) | 2007-12-07 | 2011-03-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の処方物 |
US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
RS56083B1 (sr) | 2007-12-07 | 2017-10-31 | Vertex Pharma | Proces za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina |
EP2231671B1 (en) | 2007-12-13 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2009108657A2 (en) | 2008-02-28 | 2009-09-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
PT2615085E (pt) | 2008-03-31 | 2015-10-09 | Vertex Pharma | Derivados piridilo como moduladores cftr |
GB0813709D0 (en) | 2008-07-26 | 2008-09-03 | Univ Dundee | Method and product |
US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
KR20110042356A (ko) | 2008-08-13 | 2011-04-26 | 버텍스 파마슈티칼스 인코포레이티드 | 제약 조성물 및 그의 투여 |
AR073709A1 (es) | 2008-09-29 | 2010-11-24 | Vertex Pharma | Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico |
US20110257223A1 (en) | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
JP5645834B2 (ja) | 2008-10-23 | 2014-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜コンダクタンス制御因子の修飾因子 |
KR20110074917A (ko) | 2008-10-23 | 2011-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도도 조정자의 조절인자 |
JP5645835B2 (ja) * | 2008-10-23 | 2014-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | N−(4−(7−アザビシクロ[2.2.1]ヘプタン−7−イル)−2−(トリフルオロメチル)フェニル)−4−オキソ−5−(トリフルオロメチル)−1,4−ジヒドロキノリン−3−カルボキサミドの固体形態 |
UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
ME02105B (me) | 2008-11-06 | 2015-10-20 | Vertex Pharma | Modulatori atp-vezujucih kasetnih transportera |
US8367660B2 (en) * | 2008-12-30 | 2013-02-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
DK2408749T3 (en) | 2009-03-20 | 2018-08-13 | Vertex Pharma | CYSTIC FIBROSE TRANSMEMBRAN CONDUCTOR CONTROLLER MODULATORS |
CA3071058C (en) | 2009-03-20 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
EP2427166B1 (en) | 2009-05-07 | 2013-10-16 | Gea Pharma Systems Limited | Tablet production module and method for continuous production of tablets |
NZ598277A (en) * | 2009-09-17 | 2014-03-28 | Vertex Pharma | Process for preparing azabicyclic compounds |
CN102665715A (zh) | 2009-10-22 | 2012-09-12 | 沃泰克斯药物股份有限公司 | 治疗囊性纤维化和其他慢性疾病的组合物 |
JP5789611B2 (ja) | 2009-10-23 | 2015-10-07 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを調製するためのプロセス |
AU2010310617A1 (en) * | 2009-10-23 | 2012-05-24 | Vertex Pharmaceuticals Incorporated | Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
EP2547658A1 (en) | 2010-03-19 | 2013-01-23 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
DK2826776T3 (da) | 2010-03-25 | 2020-12-14 | Vertex Pharma | Fast dispersion af amorf form af (r)-1(2,2-difluorbenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluor-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropancarboxamid |
PL2555754T3 (pl) | 2010-04-07 | 2016-09-30 | Formy stałe kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego | |
NZ602838A (en) | 2010-04-07 | 2015-06-26 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof |
WO2011133953A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
EP3138563A1 (en) | 2010-04-22 | 2017-03-08 | Vertex Pharmaceuticals Inc. | Pharmaceutical compositions and administrations thereof |
JP2013525371A (ja) | 2010-04-22 | 2013-06-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | シクロアルキルカルボキサミド−インドール化合物の製造方法 |
CA2796646A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
US8404849B2 (en) | 2010-05-20 | 2013-03-26 | Vertex Pharmaceuticals | Processes for producing modulators of cystic fibrosis transmembrane conductance regulator |
CA2798412A1 (en) | 2010-05-20 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
RU2013112937A (ru) | 2010-08-23 | 2014-09-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтические композиции (r)-1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)-n-(2, 3-дигидроксипропил)-6-фтор-2-(1-гидрокси-2-метилпропан-2-ил)-1н-индол-5-ил)циклопропанкарбоксамида и их применение |
CN103153286A (zh) | 2010-08-27 | 2013-06-12 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
EP2773349A1 (en) | 2011-11-02 | 2014-09-10 | Vertex Pharmaceuticals Incorporated | Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases |
US9254291B2 (en) | 2011-11-08 | 2016-02-09 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US20140127901A1 (en) | 2012-11-08 | 2014-05-08 | Taiwan Semiconductor Manufacturing Company, Ltd. | Low-k damage free integration scheme for copper interconnects |
JP2015504920A (ja) | 2012-01-25 | 2015-02-16 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の製剤 |
AU2013226076B2 (en) | 2012-02-27 | 2017-11-16 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
AU2013270681A1 (en) | 2012-06-08 | 2014-12-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of CFTR -mediated disorders |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
SG10201703452PA (en) | 2012-11-02 | 2017-06-29 | Vertex Pharma | Pharmaceutical compositions for the treatment of cftr mediated diseases |
US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
EP4223294A1 (en) | 2014-04-15 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
LT3203840T (lt) | 2014-10-06 | 2020-10-26 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai |
EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
WO2016086136A1 (en) | 2014-11-26 | 2016-06-02 | Catabasis Pharmaceuticals, Inc. | Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders |
MA41031A (fr) | 2014-11-26 | 2017-10-03 | Catabasis Pharmaceuticals Inc | Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie |
EP3226861A2 (en) | 2014-12-05 | 2017-10-11 | Centre National de la Recherche Scientifique (CNRS) | Compounds for treating cystic fibrosis |
WO2016123028A1 (en) | 2015-01-26 | 2016-08-04 | Rigel Pharmaceuticals, Inc. | Tetrazolones as carboxylic acid bioisosteres |
UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
-
2008
- 2008-12-04 RS RS20170588A patent/RS56083B1/sr unknown
- 2008-12-04 MX MX2013009270A patent/MX365732B/es unknown
- 2008-12-04 DK DK12196511.5T patent/DK2639223T3/en active
- 2008-12-04 HU HUE12196511A patent/HUE032268T2/en unknown
- 2008-12-04 CA CA2989620A patent/CA2989620C/en active Active
- 2008-12-04 RS RS20160784A patent/RS55298B1/sr unknown
- 2008-12-04 CA CA3147290A patent/CA3147290A1/en active Pending
- 2008-12-04 ES ES12196539.6T patent/ES2604555T3/es active Active
- 2008-12-04 SI SI200831820A patent/SI2639223T1/sl unknown
- 2008-12-04 CA CA2707494A patent/CA2707494C/en active Active
- 2008-12-04 RS RS20160828A patent/RS55360B1/sr unknown
- 2008-12-04 PT PT121965396T patent/PT2639224T/pt unknown
- 2008-12-04 EA EA201070700A patent/EA201070700A1/ru unknown
- 2008-12-04 SI SI200831715A patent/SI2639224T1/sl unknown
- 2008-12-04 PT PT88595822T patent/PT2231606E/pt unknown
- 2008-12-04 MX MX2013009273A patent/MX364936B/es unknown
- 2008-12-04 RS RS20130184A patent/RS52759B/en unknown
- 2008-12-04 LT LTEP12196511.5T patent/LT2639223T/lt unknown
- 2008-12-04 EP EP12196502.4A patent/EP2639222B1/en active Active
- 2008-12-04 KR KR1020157014536A patent/KR20150066608A/ko not_active Application Discontinuation
- 2008-12-04 PL PL12196539T patent/PL2639224T3/pl unknown
- 2008-12-04 LT LTEP12196502.4T patent/LT2639222T/lt unknown
- 2008-12-04 DK DK12196502.4T patent/DK2639222T3/en active
- 2008-12-04 PL PL12196511T patent/PL2639223T3/pl unknown
- 2008-12-04 NZ NZ599684A patent/NZ599684A/xx unknown
- 2008-12-04 WO PCT/US2008/085458 patent/WO2009076142A2/en active Application Filing
- 2008-12-04 ES ES12196511.5T patent/ES2625957T3/es active Active
- 2008-12-04 PT PT121965115T patent/PT2639223T/pt unknown
- 2008-12-04 EP EP12196511.5A patent/EP2639223B1/en active Active
- 2008-12-04 MX MX2010006183A patent/MX2010006183A/es active IP Right Grant
- 2008-12-04 CN CN200880124151.0A patent/CN101910134B/zh active Active
- 2008-12-04 ES ES12196502.4T patent/ES2604178T3/es active Active
- 2008-12-04 MX MX2013009269A patent/MX364935B/es unknown
- 2008-12-04 BR BRPI0820902-2A patent/BRPI0820902A2/pt not_active Application Discontinuation
- 2008-12-04 US US12/327,915 patent/US8124781B2/en active Active
- 2008-12-04 JP JP2010537039A patent/JP5702149B2/ja active Active
- 2008-12-04 EP EP08859582A patent/EP2231606B1/en active Active
- 2008-12-04 AU AU2008335440A patent/AU2008335440B2/en active Active
- 2008-12-04 PT PT121965024T patent/PT2639222T/pt unknown
- 2008-12-04 PL PL08859582T patent/PL2231606T3/pl unknown
- 2008-12-04 SI SI200830952T patent/SI2231606T1/sl unknown
- 2008-12-04 DK DK08859582.2T patent/DK2231606T3/da active
- 2008-12-04 LT LTEP12196539.6T patent/LT2639224T/lt unknown
- 2008-12-04 HU HUE12196539A patent/HUE029775T2/en unknown
- 2008-12-04 DK DK12196539.6T patent/DK2639224T3/en active
- 2008-12-04 PL PL12196502T patent/PL2639222T3/pl unknown
- 2008-12-04 NZ NZ612635A patent/NZ612635A/en unknown
- 2008-12-04 HU HUE12196502A patent/HUE031871T2/en unknown
- 2008-12-04 EP EP12196539.6A patent/EP2639224B1/en active Active
- 2008-12-04 SI SI200831706A patent/SI2639222T1/sl unknown
- 2008-12-04 NZ NZ585794A patent/NZ585794A/en unknown
- 2008-12-04 KR KR1020107015002A patent/KR101612009B1/ko active IP Right Grant
- 2008-12-04 CN CN201410048078.0A patent/CN103864678B/zh active Active
- 2008-12-04 KR KR1020167009109A patent/KR101674404B1/ko active IP Right Grant
- 2008-12-04 ES ES08859582T patent/ES2406940T3/es active Active
-
2010
- 2010-05-21 ZA ZA2010/03624A patent/ZA201003624B/en unknown
- 2010-06-06 IL IL206205A patent/IL206205A/en active IP Right Grant
- 2010-06-16 CL CL2010000631A patent/CL2010000631A1/es unknown
-
2011
- 2011-01-14 HK HK11100362.7A patent/HK1146820A1/xx unknown
-
2012
- 2012-01-17 US US13/351,573 patent/US8592602B2/en active Active
-
2013
- 2013-05-10 HR HRP20130418AT patent/HRP20130418T1/hr unknown
- 2013-05-13 CY CY20131100380T patent/CY1113985T1/el unknown
- 2013-05-19 IL IL226411A patent/IL226411A/en active IP Right Grant
- 2013-05-19 IL IL226410A patent/IL226410A/en active IP Right Grant
- 2013-05-19 IL IL226412A patent/IL226412A/en active IP Right Grant
- 2013-10-23 US US14/061,004 patent/US9321725B2/en active Active
- 2013-12-06 JP JP2013252770A patent/JP5797726B2/ja active Active
-
2014
- 2014-11-27 JP JP2014239562A patent/JP2015044854A/ja active Pending
- 2014-12-10 HK HK14112410.1A patent/HK1199019A1/xx unknown
-
2015
- 2015-11-16 JP JP2015223684A patent/JP2016026233A/ja active Pending
-
2016
- 2016-03-17 US US15/073,591 patent/US9776968B2/en active Active
- 2016-11-21 HR HRP20161543TT patent/HRP20161543T1/hr unknown
- 2016-11-22 CY CY20161101202T patent/CY1118332T1/el unknown
- 2016-11-24 HR HRP20161572TT patent/HRP20161572T1/hr unknown
- 2016-11-30 CY CY20161101240T patent/CY1118310T1/el unknown
-
2017
- 2017-06-05 HR HRP20170851TT patent/HRP20170851T1/hr unknown
- 2017-06-15 CY CY20171100629T patent/CY1118992T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170851T1 (hr) | Postupak za proizvodnju cikloalkilkarboksiamido-piridin benzojevih kiselina | |
CN103562193A (zh) | 合成酮基-苯并呋喃衍生物的方法 | |
CN107573267B (zh) | 含有三氟甲基的烷基磺酰氟化合物、其制备方法和应用 | |
CN106459087A (zh) | 活化的凝血因子X (FXa)抑制剂的制备方法 | |
RU2011121239A (ru) | Способ получения производных гиалуроновой кислоты | |
PL215879B1 (pl) | Sposób syntezy przemyslowej tetraestrów kwasu 5-[bis(karboksymetylo)amino]-3-karboksymetylo-4-cyjano-2-tiofenokarboksylowego oraz zwiazek posredni 5-[bis(2-metoksy-2-oksoetylo)amino]-4-cyjano-3-(2-metoksy-2-oksoetylo)-2-tiofenokarboksylan metylu | |
KR20090032009A (ko) | 스트론튬 라넬레이트 및 이의 수화물의 합성 방법 | |
RU2005125724A (ru) | Способ получения фармацевтических средств и соединения, полученные данным способом | |
CN107445795B (zh) | 一种2-溴-1,1,2,2-四氟乙基取代的芳基砌块的合成方法 | |
SI2681192T1 (en) | Synthesis of the 2-carboxamide cycloamino derivatives derivatives | |
US20120157716A1 (en) | Methods for Preparing Diaryl Disulfides | |
KR20120071339A (ko) | 벤다무스틴 알킬 에스테르, 벤다무스틴, 및 이의 유도체의 제조 방법 | |
CN112661584A (zh) | 一种光催化n-烷基酰胺化合物的制备方法 | |
WO2013072938A2 (en) | An improved process for the preparation of roflumilast | |
EP0968189B1 (en) | Process for the preparation of nicotinic acids | |
CN112979581B (zh) | 可见光促进的n-(2-溴苯基)硫代酰胺制备苯并噻唑类化合物的方法 | |
CN109574778B (zh) | 一种布瓦西坦及其中间体的制备方法 | |
CN110498762A (zh) | 一种(2s,5r)-5-[(苄氧基)氨基]-哌啶-2-甲酸乙酯的合成方法 | |
CA2514900A1 (en) | Process for the preparation of 2-[(diphenylmethyl) thio] acetamide | |
IT9047829A1 (it) | Metodo per la preparazione di eteni sostituiti, utili in particolare come intermedi nella produzione di ranitidina. | |
CN104788337A (zh) | 酰亚胺类化合物的合成方法 | |
JP2013241345A (ja) | トリフルオロメチル化剤、その製造方法並びにそれを用いたトリフルオロメチル基含有化合物の製造方法 | |
ITMI992157A1 (it) | Processo per la preparazione di intermedi utili nella sintesi di diarilpiridine | |
CN111100111B (zh) | 一种制备苯并噻吩衍生物的方法 | |
EP3354645A1 (en) | Process for preparing urolithins |